MetLife Investment Management’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $419K | Hold |
20,761
| – | – | ﹤0.01% | 2021 |
|
|
2026
Q1 | $407K | Sell |
20,761
-314
| -1% | -$7.68K | ﹤0.01% | 1847 |
|
|
2025
Q4 | $564K | Sell |
21,075
-2,018
| -9% | -$52K | ﹤0.01% | 1736 |
|
|
2025
Q3 | $615K | Hold |
23,093
| – | – | ﹤0.01% | 1703 |
|
|
2025
Q2 | $530K | Hold |
23,093
| – | – | ﹤0.01% | 1653 |
|
|
2025
Q1 | $669K | Sell |
23,093
-359
| -2% | -$11.5K | ﹤0.01% | 1563 |
|
|
2024
Q4 | $871K | Buy |
23,452
+845
| +4% | +$38.6K | ﹤0.01% | 1491 |
|
|
2024
Q3 | $1.1M | Hold |
22,607
| – | – | 0.01% | 1342 |
|
|
2024
Q2 | $904K | Buy |
22,607
+3,090
| +16% | +$128K | 0.01% | 1394 |
|
|
2024
Q1 | $857K | Sell |
19,517
-950
| -5% | -$49.1K | 0.01% | 1385 |
|
|
2023
Q4 | $1.27M | Hold |
20,467
| – | – | 0.01% | 1178 |
|
|
2023
Q3 | $941K | Hold |
20,467
| – | – | 0.01% | 1262 |
|
|
2023
Q2 | $1.18M | Hold |
20,467
| – | – | 0.01% | 1172 |
|
|
2023
Q1 | $768K | Hold |
20,467
| – | – | 0.01% | 1379 |
|
|
2022
Q4 | $573K | Hold |
20,467
| – | – | ﹤0.01% | 1555 |
|
|
2022
Q3 | $575K | Hold |
20,467
| – | – | ﹤0.01% | 1534 |
|
|
2022
Q2 | $712K | Hold |
20,467
| – | – | 0.01% | 1420 |
|
|
2022
Q1 | $735K | Buy |
20,467
+8,664
| +73% | +$246K | ﹤0.01% | 1528 |
|
|
2021
Q4 | $275K | Hold |
11,803
| – | – | ﹤0.01% | 1855 |
|
|
2021
Q3 | $224K | Hold |
11,803
| – | – | ﹤0.01% | 2014 |
|
|
2021
Q2 | $238K | Hold |
11,803
| – | – | ﹤0.01% | 2043 |
|
|
2021
Q1 | $216K | Sell |
11,803
-6,402
| -35% | -$119K | ﹤0.01% | 2014 |
|
|
2020
Q4 | $366K | Hold |
18,205
| – | – | ﹤0.01% | 1638 |
|
|
2020
Q3 | $341K | Hold |
18,205
| – | – | ﹤0.01% | 1564 |
|
|
2020
Q2 | $409K | Hold |
18,205
| – | – | ﹤0.01% | 1491 |
|
|
2020
Q1 | $270K | Hold |
18,205
| – | – | ﹤0.01% | 1534 |
|
|
2019
Q4 | $351K | Hold |
18,205
| – | – | ﹤0.01% | 1649 |
|
|
2019
Q3 | $361K | Hold |
18,205
| – | – | ﹤0.01% | 1591 |
|
|
2019
Q2 | $384K | Sell |
18,205
-36,410
| -67% | -$761K | ﹤0.01% | 1635 |
|
|
2019
Q1 | $1.12M | Buy |
54,615
+36,410
| +200% | +$816K | ﹤0.01% | 1598 |
|
|
2018
Q4 | $362K | Hold |
18,205
| – | – | ﹤0.01% | 1557 |
|
|
2018
Q3 | $350K | Hold |
18,205
| – | – | ﹤0.01% | 1757 |
|
|
2018
Q2 | $278K | Hold |
18,205
| – | – | ﹤0.01% | 1749 |
|
|
2018
Q1 | $341K | Hold |
18,205
| – | – | ﹤0.01% | 1610 |
|
|
2017
Q4 | $350K | Buy |
+18,205
| New | +$340K | ﹤0.01% | 1618 |
|
Other funds holding AMPH
MetLife Investment Management's AMPH Position: Q2 2026 in Review
MetLife Investment Management held its Amphastar Pharmaceuticals (AMPH) position steady in Q2 2026 at 20,761 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #2021.
MetLife Investment Management first reported a position in AMPH in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.27M in Q4 2023. 211 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.
- MetLife Investment Management held 20,761 shares of Amphastar Pharmaceuticals worth $419K as of Q2 2026.
- MetLife Investment Management left its Amphastar Pharmaceuticals share count unchanged in Q2 2026.
- Amphastar Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2021 holding.
- MetLife Investment Management first reported a position in Amphastar Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Amphastar Pharmaceuticals position peaked at $1.27M in Q4 2023.
- 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.